Announcement

Collapse
No announcement yet.

Merck loses bid to revive $200 million Gilead verdict at U.S. high court

Collapse
X
  • Filter
  • Time
  • Show
Clear All
new posts

  • Merck loses bid to revive $200 million Gilead verdict at U.S. high court

    The U.S. Supreme Court regarding Monday handed a destroy to Merck & Co (N:MRK) by refusing to hear its appeal of a ruling that it had dishonestly obtained patent rights and could not merge a $200 million verdict adjoining challenger drugmaker Gilead Sciences Inc (O:GILD) in a argument involving blockbuster hepatitis C drugs.

    Our Official Website: Trade Forex Copier
Working...
X